A Randomized, Double-blind, Multicenter, Phase II Study to Assess the Safety, Tolerability, and Efficacy of ZD6474 in Combination With Docetaxel (TAXOTER) in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-based Chemotherapy.
Latest Information Update: 02 Sep 2016
At a glance
- Drugs Vandetanib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Genzyme Corporation
- 17 Dec 2007 The expected completion date for this trial is now 1 Sep 2006.
- 03 Sep 2005 New trial record.